<DOC>
	<DOC>NCT01901289</DOC>
	<brief_summary>The Zilver速 PTX速 V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.</brief_summary>
	<brief_title>Zilver速 PTX速 V Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Patient has signed and dated the informed consent. Patient has symptomatic vascular disease of the native abovetheknee femoropopliteal arteries. Patient agrees to return for the required followup assessments. Patient is &lt; 18 years of age. Patient has significant stenosis of inflow tract not successfully treated before this procedure. Patient lacks at least one patent vessel of runoff with &lt; 50% stenosis throughout its course.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Femoral Artery</keyword>
	<keyword>Popliteal Artery</keyword>
	<keyword>Drug-Eluting Stent</keyword>
</DOC>